XOMA Corp

NASDAQ: XOMA    
Share price (5/17/24): $25.51    
Market cap (5/17/24): $297 million
Search in Documents
Key Exhibits
External Links
2 XOMA Corp Expert Interviews, now on BamSEC.
 Powered by Tegus.

Material Contracts Filter

EX-10.3
from 10-Q 3 pages Certain Identified Information Has Been Excluded (Indicated By: [***]) From the Exhibit Because It Is Both (I) Not Material and (II) the Type of Information That the Registrant Customarily and Actually Treats as Private or Confidential ​ Amendment No. 1 to Royalty Purchase Agreement
12/34/56
EX-10.2
from 10-Q 50 pages Certain Identified Information Has Been Excluded (Indicated By: [***]) From the Exhibit Because It Is Both (I) Not Material and (II) the Type of Information That the Registrant Customarily and Actually Treats as Private or Confidential
12/34/56
EX-10.65
from 10-K 11 pages R E C I T a L S
12/34/56
EX-10.64
from 10-K 24 pages Sale, Contribution and Servicing Agreement Dated as of December 15, 2023 Between XOMA (US) LLC, as Seller, and Solely for Purposes of ‎section 2.03 and ‎section 4.03(b)(ii), XOMA Corporation, as Parent, on the One Hand and Xrl 1 LLC, as Purchaser, on the Other Hand ​
12/34/56
EX-10.16
from 10-K 17 pages Amended and Restated Officer Employment Agreement
12/34/56
EX-10.10
from 10-K 1 page ​ November 1, 2022 ​ Thomas Burns via Email/Docusign ​ Dear Thomas: ​
12/34/56
EX-10.4
from 10-Q 45 pages Certain Identified Information Has Been Excluded (Indicated By: [***]) From the Exhibit Because It Is Both (I) Not Material and (II) the Type of Information That the Registrant Customarily and Actually Treats as Private or Confidential
12/34/56
EX-10.3
from 10-Q 29 pages Recitals
12/34/56
EX-10.1
from 8-K 7 pages Performance Unit Agreement XOMA Corporation Amended and Restated 2010 Long Term Incentive and Stock Award Plan
12/34/56
EX-10.7
from 10-Q 40 pages ​ Certain Identified Information Has Been Excluded (Indicated By: [***]) From the Exhibit Because It Is Both (I) Not Material and (II) the Type of Information That the Registrant Customarily and Actually Treats as Private or Confidential
12/34/56
EX-10.58
from 10-K 28 pages License Agreement Dated June 10, 2015 by and Between Ares Trading S.A. and Obseva S.A
12/34/56
EX-10.57
from 10-K 62 pages License Agreement
12/34/56
EX-10.56
from 10-K 18 pages Ip Acquisition Agreement
12/34/56
EX-10.16
from 10-K 18 pages Officer Employment Agreement
12/34/56
EX-10.15
from 10-K 12 pages Officer Employment Agreement
12/34/56
EX-10.14
from 10-K 18 pages XOMA Corporation Amended and Restated Retention and Severance Plan
12/34/56
EX-10.10
from 10-K 1 page ​ November 1, 2022 ​ Thomas Burns via Email/Docusign ​ Dear Thomas: ​
12/34/56
EX-10.4
from 10-Q 3 pages Amendment and Restatement to Agreements
12/34/56
EX-10.3
from 10-Q 11 pages ​ ​ ​ ​ ​ ​ ​ Nanotherapeutics License Agreement, by and Between XOMA (US) LLC and Nanotherapeutics, Inc. March 23, 2016
12/34/56
EX-10.2
from 10-Q 63 pages ​ License Agreement ​ by and Between XOMA (US) LLC and ​ Novartis Pharma AG
12/34/56